Mersana Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on cancer therapies, will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 12:50 p.m. ET. The presentation will be accessible via a live webcast on their website, with an archived replay available for 30 days. Mersana's lead candidate, upifitamab rilsodotin, is being evaluated in pivotal trials for ovarian cancer, while the company continues to develop additional antibody drug conjugates (ADCs) targeting NaPi2b and other cancer-related pathways.

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Company will participate in a virtual panel presentation at the Cowen 42^nd Annual Health Care Conference on Wednesday, March 9, 2022 at 12:50 p.m. ET.

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 30 days following the presentation.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose exploration portion of a Phase 1 clinical trial. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana Therapeutics was recently named among the 2021 Top Places to Work in Massachusetts by the Boston Globe. The Company routinely posts information that may be useful to investors on the “Investors and Media” section of our website at www.mersana.com.

Contact:

Investor & Media Contact
James Salierno, 617-498-0020
jsalierno@mersana.com

FAQ

When will Mersana participate in the Cowen 42nd Annual Health Care Conference?

Mersana will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 12:50 p.m. ET.

Where can I watch Mersana's presentation from the Cowen Conference?

The presentation can be viewed via a live webcast on Mersana's website.

What is Mersana's lead product candidate?

Mersana's lead product candidate is upifitamab rilsodotin (UpRi), targeting NaPi2b in patients with platinum-resistant ovarian cancer.

What is the focus of Mersana Therapeutics?

Mersana Therapeutics focuses on developing antibody drug conjugates (ADCs) for cancer treatments with high unmet medical needs.

What trials are Mersana's ADCs currently involved in?

Mersana's lead candidate is being studied in the UPLIFT trial for ovarian cancer and the UPGRADE Phase 1/2 trial evaluating combinations with other therapies.